Gene · 22925
Papers2,349
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,349
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparison of the efficacy of obinutuzumab versus rituximab combined with tacrolimus in the treatment of refractory membranous nephropathy. | BMC Nephrol | 2026 | 42106625 | PubTator, text mining | PubMed |
| Efficacy and safety of modified-dose obinutuzumab in the treatment of refractory membranous nephropathy. | Front Immunol | 2026 | 42099618 | PubTator, text mining | PubMed |
| Persistent red fluorescence interference in anti-PLA2R indirect immunofluorescence assays associated with liposomal doxorubicin. | Clin Biochem | 2026 | 42097480 | PubTator, text mining | PubMed |
| Obinutuzumab versus rituximab in refractory membranous nephropathy: a single-center retrospective cohort study. | BMC Nephrol | 2026 | 42062984 | PubTator, text mining | PubMed |
| Obinutuzumab after anti-rituximab antibody-associated treatment failure in membranous nephropathy: a case report. | Front Immunol | 2026 | 42051525 | PubTator, text mining | PubMed |
| A Case of Minimal Change Disease Superimposed on Stable Membranous Nephropathy Following the Third Dose of COVID-19 mRNA Vaccine in a Patient With Type 2 Diabetes. | Nephrology (Carlton) | 2026 | 42047308 | PubTator, text mining | PubMed |
| The value of renal biopsy in PLA2R- antibody-positive patients with proteinuria: impact of additional pathologies on management and prognosis in a Chinese Cohort. | Front Physiol | 2026 | 42046787 | PubTator, text mining | PubMed |
| Anti-PLA2R antibodies: implications for therapeutic planning and the prediction of remission in membranous nephropathy. | J Bras Nefrol | 2026 | 42044302 | PubTator, text mining | PubMed |
| PLA2R-Positive Membranous Nephropathy and AA Amyloidosis in an Ethiopian Patient With Chronic Hepatitis B: A Case Report. | Clin Case Rep | 2026 | 42040394 | PubTator, text mining | PubMed |
| Membranous Nephropathy Preceding Systemic Sclerosis: An Unusual Presentation of Systemic Sclerosis sine Scleroderma. | G Ital Nefrol | 2026 | 42037288 | PubTator, text mining | PubMed |
| Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy. | Kidney Int Rep | 2026 | 42027554 | PubTator, text mining | PubMed |
| Protocadherin FAT1-associated membranous nephropathy after hematopoietic stem cell transplantation-a cohort study with clinico-pathological correlations. | Clin Kidney J | 2026 | 42022276 | PubTator, text mining | PubMed |
| Early kinetics of anti-PLA2R-IgG4 predicts rituximab response in membranous nephropathy: a prospective biomarker study. | Sci Rep | 2026 | 41998044 | PubTator, text mining | PubMed |
| Spontaneous Remission of Late Relapsing Membranous Nephropathy After Previous Immunosuppressant-Induced Remission: Case Report. | Case Rep Nephrol | 2026 | 41982503 | PubTator, text mining | PubMed |
| Delayed but durable remission to rituximab in PLA2R-associated membranous nephropathy despite B-cell reconstitution: a case report. | BMC Nephrol | 2026 | 41975315 | PubTator, text mining | PubMed |
| Evolution of idiopathic membranous nephropathy to class v lupus nephritis: a case report and literature review. | Front Med (Lausanne) | 2026 | 41948588 | PubTator, text mining | PubMed |
| Obinutuzumab Treatment in Rituximab- and Bortezomib-Resistant Phospholipase A2 Receptor Antibody-Positive Membranous Nephropathy. | Cureus | 2026 | 41909433 | PubTator, text mining | PubMed |
| Serine protease HTRA1 is a common autoantigen in membranous nephropathy in patients of 80 years and older. | Kidney Int | 2026 | 41905594 | PubTator, text mining | PubMed |
| Prognostic Stratification in Primary Glomerulonephritis: Integrating Histology, Biomarkers, and Risk Prediction Models. | Life (Basel) | 2026 | 41900938 | PubTator, text mining | PubMed |
| Comparison of the efficacy of low, moderate and standard doses of rituximab in the treatment of membranous nephropathy. | Front Med (Lausanne) | 2026 | 41889528 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/22925/papers?page=4